Experimental Gene Therapy Uses Brain Surgery to Achieve Results For Huntington’s Disease Patients, Part One
source: pixabay.com

Experimental Gene Therapy Uses Brain Surgery to Achieve Results For Huntington’s Disease Patients, Part One

When we ‘do the math’ it adds up to the novel AMT-130 gene therapy receiving positive results from uniQure’s clinical trial investigating a small group (N=4) of individuals who were…

Continue Reading Experimental Gene Therapy Uses Brain Surgery to Achieve Results For Huntington’s Disease Patients, Part One
Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers
source: pixabay.com

Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers

  Dr. Jung-Mo Ahn, associate professor at Dallas University in Texas, created a molecule that kills a broad range of treatment-resistant cancers. The newly targeted group includes triple-negative breast cancer.…

Continue Reading Dallas University Researcher and Colleagues Create a Molecule That Kills a Wide Range of Treatment-Resistant Cancers
UC San Diego Health First in US to Offer Amvuttra for ATTR Amyloidosis
whitesession / Pixabay

UC San Diego Health First in US to Offer Amvuttra for ATTR Amyloidosis

  In June 2022, the FDA approved Amvuttra, a prescription medicine designed to treat polyneuropathy (nerve damage) due to hereditary transthyretin amyloidosis (hATTR amyloidosis). This approval was huge. Typically, managing…

Continue Reading UC San Diego Health First in US to Offer Amvuttra for ATTR Amyloidosis
The FDA Grants Approval to Begin Dosing First-in-Human CRISPR Technology to Treat Duchenne Muscular Dystrophy
source: pixabay.com

The FDA Grants Approval to Begin Dosing First-in-Human CRISPR Technology to Treat Duchenne Muscular Dystrophy

   Business Wire published an August 10th news release announcing that Cure Rare Disease, a non-profit based in Boston, Massachusetts received FDA approval to administer CRD-TMH-001 (CRD), its first-ever therapeutic.…

Continue Reading The FDA Grants Approval to Begin Dosing First-in-Human CRISPR Technology to Treat Duchenne Muscular Dystrophy
New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany
source: unsplash.com

New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany

According to a story from Benzinga, the pharmaceutical company Inceptua Group has recently announced that the medicine paclitaxel micellar (marketed as Apealea) is now available in Germany. This medication is…

Continue Reading New Treatment Formulation for Ovarian Cancer and Other Rare Cancers Available in Germany
Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor
source: pixabay.com

Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor

  Karyopharm Therapeutics, a pharmaceutical company focusing on novel cancer therapies, has issued a statement via PR Newswire that the FDA has granted regulatory designations to eltanexor, Karyopharm’s Selective Inhibitor…

Continue Reading Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor
First Participant Dosed in IMG-004 Trial for Immunological Diseases
source: pixabay.com

First Participant Dosed in IMG-004 Trial for Immunological Diseases

  Near the start of August 2022, biotechnology company Inmagene Biopharmaceuticals ("Inmagene") and biopharmaceutical company HUTCHMED shared via news release that the first participant had been dosed in a Phase…

Continue Reading First Participant Dosed in IMG-004 Trial for Immunological Diseases

FDA Approves Bylvay for Treatment of Progressive Familial Intrahepatic Cholestasis

  According to a recent press release from Globe Newswire, Albireo Pharma announced that Lancet Gastroenterology published results of the PEDFIC 1 trial evaluating Bylvay® in the treatment of progressive…

Continue Reading FDA Approves Bylvay for Treatment of Progressive Familial Intrahepatic Cholestasis